Whether ruxolitinib cream (Opzelura) is a targeted drug and a detailed explanation of its mechanism of action

Ruxolitinib cream (Opzelura) is a new type of topical drug mainly used to treat specific types of skin diseases, such as idiopathic vitiligo and chronic inflammatory skin diseases. Strictly speaking, ruxolitinib is not an anti-tumor targeted drug in the traditional sense, but a type of topical preparation of tyrosine kinase inhibitors (JAKinhibitors). It specifically acts on intracellular signaling pathways to regulate immune and inflammatory responses at the molecular level, thereby improving the symptoms of skin diseases.

The main mechanism of action of ruxolitinib is to inhibit the signaling of the Janus kinase (JAK) family. JAK-STATThe signaling pathway plays a key role in a variety of immune regulation and inflammatory responses. In autoimmune skin diseases such as vitiligo, excessive activation of the JAK-STAT pathway promotes the release of inflammatory factors, causing damage or abnormal function of skin pigment cells. Ruxolitinib reduces immune-mediated damage, protects melanocytes, and promotes pigment recovery by locally inhibiting JAK kinase activity and blocking signaling.

Clinical studies have shown that topical use of ruxolitinib cream can significantly improve pigment recovery and skin inflammatory response in the lesion area. Compared with oral JAK inhibitors, topical formulations apply the drug directly to the skin lesion area, reducing systemic exposure and thereby reducing the risk of systemic side effects. Research data shows that after 8 to 24 weeks of topical application, the patient’s white spot area was significantly reduced, and the skin tolerated it well. Most adverse reactions were mild irritation or local erythema, and were reversible.

In general, ruxolitinib cream achieves local immune regulation and anti-inflammatory effects by precisely inhibiting the JAK-STAT pathway, thereby improving the symptoms of vitiligo and chronic inflammatory skin diseases. It is a topical drug with a molecular targeting mechanism, but unlike tumor-targeting drugs, it is mainly used for skin immune regulation rather than anti-tumor. Its local application characteristics enable it to reduce systemic side effects while ensuring efficacy, providing patients with a safe and efficient topical treatment option.

Reference materials:https://www.drugs.com/